These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 11108944

  • 1. Immunomodulatory effects of interferon beta-1a in multiple sclerosis.
    Liu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA.
    J Neuroimmunol; 2001 Jan 01; 112(1-2):153-62. PubMed ID: 11108944
    [Abstract] [Full Text] [Related]

  • 2. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.
    Filion LG, Matusevicius D, Graziani-Bowering GM, Kumar A, Freedman MS.
    Clin Immunol; 2003 Feb 01; 106(2):127-38. PubMed ID: 12672403
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta.
    Shapiro S, Galboiz Y, Lahat N, Kinarty A, Miller A.
    J Neuroimmunol; 2003 Nov 01; 144(1-2):116-24. PubMed ID: 14597105
    [Abstract] [Full Text] [Related]

  • 7. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A.
    Clin Exp Immunol; 2004 Dec 01; 138(3):499-506. PubMed ID: 15544628
    [Abstract] [Full Text] [Related]

  • 8. A novel population of B7-1+ T cells producing intracellular IL-4 is decreased in patients with multiple sclerosis.
    Kipp B, Bar-Or A, Gausling R, Oliveira EM, Fruhan SA, Stuart WH, Hafler DA.
    Eur J Immunol; 2000 Jul 01; 30(7):2092-100. PubMed ID: 10940899
    [Abstract] [Full Text] [Related]

  • 9. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B, Jacobs LD.
    Drugs; 2000 Mar 01; 59(3):401-10. PubMed ID: 10776827
    [Abstract] [Full Text] [Related]

  • 10. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2004 Oct 01; 155(1-2):172-82. PubMed ID: 15342209
    [Abstract] [Full Text] [Related]

  • 11. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment.
    Teleshova N, Bao W, Kivisäkk P, Ozenci V, Mustafa M, Link H.
    Scand J Immunol; 2000 Mar 01; 51(3):312-20. PubMed ID: 10736102
    [Abstract] [Full Text] [Related]

  • 12. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
    Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisäkk P, Fredrikson S, Link H.
    Scand J Immunol; 1999 May 01; 49(5):554-61. PubMed ID: 10320650
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X.
    J Neurol; 2005 Jul 01; 252(7):795-800. PubMed ID: 15772741
    [Abstract] [Full Text] [Related]

  • 15. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A.
    Mult Scler; 2008 Mar 01; 14(2):166-76. PubMed ID: 17942524
    [Abstract] [Full Text] [Related]

  • 16. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
    Reske D, Thomas AV, Petereit HF, Fink GR, Schroeter M.
    Neuroimmunomodulation; 2009 Mar 01; 16(6):385-91. PubMed ID: 19609087
    [Abstract] [Full Text] [Related]

  • 17. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.
    J Neurol Sci; 2004 Jul 15; 222(1-2):65-73. PubMed ID: 15240198
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis.
    Sharief MK, Semra YK.
    Arch Neurol; 2002 Jul 15; 59(7):1115-21. PubMed ID: 12117359
    [Abstract] [Full Text] [Related]

  • 19. Regulation of CD40 ligand expression on naive CD4 T cells: a role for TCR but not co-stimulatory signals.
    Jaiswal AI, Dubey C, Swain SL, Croft M.
    Int Immunol; 1996 Feb 15; 8(2):275-85. PubMed ID: 8671613
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH.
    J Neuroimmunol; 1999 Jan 01; 93(1-2):8-14. PubMed ID: 10378864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.